检索结果 - Nilla Avanzi

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515

    Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515 由 Gianluca Papeo, Paolo Orsini, Nilla Avanzi, Daniela Borghi, Elena Casale, Marina Ciomei, Alessandra Cirla, Viviana Desperati, Daniele Donati, Eduard Felder, Arturo Galvani, Marco Guanci, Antonella Isacchi, Helena Posteri, Sonia Rainoldi, Federico Riccardi Sirtori, Alessandra Scolaro, Alessia Montagnoli

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

    Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy 由 Clara Albanese, Rachele Alzani, Nadia Amboldi, Nilla Avanzi, Dario Ballinari, Maria Gabriella Brasca, Claudio Festuccia, Francesco Fiorentini, Giuseppe Locatelli, Wilma Pastori, Veronica Patton, Fulvia Roletto, Francesco Colotta, Arturo Galvani, Antonella Isacchi, Jürgen Moll, Enrico Pesenti, Ciro Mercurio, Marina Ciomei

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase

    Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase 由 Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi, Maria Laura Giorgini, Francesco Sola, Paolo Cappella, Claudia Perrera, Stefania Re Depaolini, Luisa Rusconi, Ulisse Cucchi, Nilla Avanzi, J. A. Bertrand, R Bossi, Enrico Pesenti, Arturo Galvani, Antonella Isacchi, Francesco Colotta, Daniele Donati, Jürgen Moll

    出版 2010
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury

    Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury 由 Melanie Deutsch, Christopher S. Graffeo, Rae S. Rokosh, Mridul Pansari, Atsuo Ochi, Elliot Levie, E Van Heerden, Daniel Tippens, Salvatore Greco, Rocky Barilla, Lena Tomkötter, Constantinos P. Zambirinis, Nilla Avanzi, Rishabh Gulati, H. Leon Pachter, Alejandro Torres-Hernandez, Andrew Eisenthal, Donnele Daley, George Miller

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

    NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies 由 Barbara Valsasina, Italo Beria, Cristina Alli, Rachele Alzani, Nilla Avanzi, Dario Ballinari, Paolo Cappella, Michele Caruso, Alessia Casolaro, Antonella Ciavolella, Ulisse Cucchi, Anna De Ponti, Eduard Felder, Francesco Fiorentini, Arturo Galvani, Laura Gianellini, Maria Laura Giorgini, Antonella Isacchi, Jaqueline Lansen, Enrico Pesenti, Simona Rizzi, Maurizio Rocchetti, Francesco Sola, Jürgen Moll

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

    The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 由 Elena Ardini, Roberta Bosotti, Andrea Borgia, Cristina Ponti, Alessio Somaschini, Rosaria Cammarota, Nadia Amboldi, Laura Raddrizzani, Andrea Milani, Paola Magnaghi, Dario Ballinari, Daniele Casero, Fabio Gasparri, Patrizia Banfi, Nilla Avanzi, Maria Beatrice Saccardo, Rachele Alzani, Tiziano Bandiera, Eduard Felder, Daniele Donati, Enrico Pesenti, Andrea Sartore‐Bianchi, Marcello Gambacorta, Marco A. Pierotti, Salvatore Siena, Silvio Veronese, Arturo Galvani, Antonella Isacchi

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

    Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications 由 Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texidó, Anna Degrassi, Nilla Avanzi, Nadia Amboldi, Maria Beatrice Saccardo, Daniele Casero, Paolo Orsini, Tiziano Bandiera, Luca Mologni, David W. Anderson, Wei Ge, Jason Harris, Jean‐Michel Vernier, Gang Li, Eduard Felder, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Paola Magnaghi, Arturo Galvani

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: